Literature DB >> 18602801

The role of adipokines in liver fibrosis.

Cristiana Bertolani1, Fabio Marra.   

Abstract

Liver fibrosis is a dynamic process consisting of the chronic activation of the wound healing reaction in response to reiterated liver damage, leading to the excessive deposition of fibrillar extracellular matrix into the liver and eventually, if the cause of injury is not removed, to liver cirrhosis. The term "adipokines" identifies a group of polypeptide molecules secreted primarily by adipose tissue, which exert local, peripheral and/or central actions. Additionally to their well-established role in controlling adipose tissue physiology, adipokines have been shown to be involved in different obesity-related diseases, such as hypertension, atherosclerosis and type 2 diabetes. Accumulating data demonstrate that obesity and insulin resistance are associated with a more severe and faster progression of the fibrogenic process in different chronic liver diseases. Therefore, numerous recent studies have analyzed the role played by adipokines in the hepatic wound healing process, identifying novel roles as modulators of liver pathophysiology. This review summarizes the more significant and recent findings concerning the role played by adipocyte-derived molecules, such as leptin, adiponectin and resistin, in the liver fibrogenic process. The actions of different adipokines on the biology of liver resident cells, as well as their effects in different animal models of liver injury are discussed. The variations in the circulating levels and in the intrahepatic expression of these molecules occurring in patients with different chronic liver diseases will be also analyzed.

Entities:  

Year:  2008        PMID: 18602801     DOI: 10.1016/j.pathophys.2008.05.001

Source DB:  PubMed          Journal:  Pathophysiology        ISSN: 0928-4680


  33 in total

Review 1.  Angiogenesis and liver fibrosis.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Hepatol       Date:  2015-03-27

2.  Angiogenesis: a phenomenon which aggravates chronic liver disease progression.

Authors:  Michał Kukla
Journal:  Hepatol Int       Date:  2012-07-26       Impact factor: 6.047

Review 3.  Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis.

Authors:  Michał Kukla; Włodzimierz Mazur; Rafał J Bułdak; Krystyna Zwirska-Korczala
Journal:  Mol Med       Date:  2011-07-05       Impact factor: 6.354

4.  Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection.

Authors:  Ching-Sheng Hsu; Wei-Liang Liu; You-Chen Chao; Hans Hsienhong Lin; Tai-Chung Tseng; Chia-Chi Wang; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2015-03-12       Impact factor: 6.047

5.  The relationship between visfatin, liver inflammation, and acute phase reactants in chronic viral hepatitis B.

Authors:  Enver Yüksel; Erdem Akbal; Erdem Koçak; Ömer Akyürek; Seyfettin Köklü; Fuat Ekiz; Barış Yılmaz
Journal:  Wien Klin Wochenschr       Date:  2015-04-09       Impact factor: 1.704

Review 6.  Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy.

Authors:  Diego García-Compeán; José Alberto González-González; Fernando Javier Lavalle-González; Emmanuel Irineo González-Moreno; Jesús Zacarías Villarreal-Pérez; Héctor J Maldonado-Garza
Journal:  Dig Dis Sci       Date:  2016-02       Impact factor: 3.199

Review 7.  Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management.

Authors:  Diego Garcia-Compean; Joel Omar Jaquez-Quintana; Jose Alberto Gonzalez-Gonzalez; Hector Maldonado-Garza
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

8.  Steatosis is a lot more than holes in hepatocytes.

Authors:  Subrata Chakrabarti
Journal:  Saudi J Gastroenterol       Date:  2009-01       Impact factor: 2.485

9.  Reversal of liver fibrosis.

Authors:  Mona H Ismail; Massimo Pinzani
Journal:  Saudi J Gastroenterol       Date:  2009-01       Impact factor: 2.485

10.  Variations of serum levels of adiponectin and resistin in chronic viral hepatitis.

Authors:  M Durazzo; P Belci; G Niro; A Collo; E Grisoglio; V Ambrogio; M Spandre; R Fontana; R Gambino; M Cassader; S Bo
Journal:  J Endocrinol Invest       Date:  2013-02-27       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.